

## Preface

OVER 22 MILLION PEOPLE ARE ALIVE TODAY SUFFERING FROM CANCER and half of those cancers share a precise common molecular feature. That feature is a mutation in the *p53* gene (see chapter by Olivier et al.) that alters its function. That these mutations play a major role in the development of malignancy is supported by the tragedy of Li-Fraumeni syndrome. This devastating cancer family syndrome is caused by germ line mutations in *p53* that predispose affected individuals to the early onset of a wide range of malignancies. It is the ubiquity of *p53* alterations in so many different types of human cancer that has focused such intense interest in understanding the *p53* gene and its protein product for the last 30 years.

An enormous amount has been learnt about how *p53* functions to reduce the incidence of cancer (Zilfou and Lowe) and new therapies based upon our understanding of *p53* are now in the clinic. The intensity of investigation has produced an intellectual dilemma, which the chapters in this book attempt to resolve. Is the ubiquity of *p53* in non-neoplastic processes as apparently diverse as human reproduction (Hu), metabolism (Feng; Gottlieb and Vousden), development (Storer and Zon), drug and radiation toxicity (Gudkov and Komarova), and aging (Donehower) a unique feature of *p53* as a transcription factor (Beckerman and Prives) or does it rather reflect the immense interconnections within signaling pathways in cells and the sensitivity of the tools developed in the *p53* system to demonstrate these connections?

Starting with chapters (Belyi et al.; Rutkowski et al.) describing the origins and evolution of the *p53* family genes in invertebrates and vertebrates, which emphasize their high level of conservation, the book then explores the complexity with which that genetic information is expressed, producing many isoforms (Khoury and Bourdon) of the three family members *p53*, *p63*, and *p73* (Dötsch et al.) in vertebrates.

Lack of *p53* results in an increased incidence of cancer, while an overactive *p53* can induce accelerated aging in vertebrates. The correct regulation of the *p53* response to stress is vital for its effective function. The study of the control of *p53* has been enormously exciting and at the cutting edge of modern molecular technology, from detailed structural investigations of its folding, stability, and oligomerization (Joerger and Fersht), through to analysis of its many post translational modifications (Meek and Anderson) and its molecular partners (Lu). Two negative regulators of *p53* function, *Mdm2* and *Mdm4*, play an essential role in controlling *p53* and this has been elegantly explored in mouse models (Perry; Lozano). Remarkably, polymorphisms have been described in the *p53* system in man that reflect on all these activities and the chapter by Grochola et al. updates the provocative observations that subtle human variations in *p53* and *Mdm2*/*Mdm4* activity can affect human cancer incidence and outcome. The pace of discovery in the field is quickening rather than slackening and it has become a model system of choice for many investigations in biology (Lane and Levine). The utility of these advanced studies is beginning to be realized both in disease diagnosis and prognosis (Robles and Harris) and in drug development (Lane et al.; Gudkov and Komarova), where a number of exciting pre-clinical molecules are under evaluation and *p53* gene therapy approved in some countries. Indeed, the recent strong mouse model support for the earlier concepts that expressed mutant *p53* proteins have new “gains of function” that can drive invasion and metastasis and block differentiation coupled with increased understanding of the control of expression of mutant *p53* proteins may resolve long standing issues of interpretation of *p53*'s role in tumor pathology (Oren and Rotter).

We hope that by bringing together a unique gathering of experts this volume will provide a great introduction to the field for newcomers to the p53 family and a starting off point for vigorous debate among the converted. The many unknowns in this system that are detailed and discussed in this volume provide us all with inspiration for future work.

We are grateful to Richard Sever at the Cold Spring Harbor Laboratory Press for his vision and encouragement and to Kaaren Kockenmeister for her organization of the production of the book. We would also like to acknowledge Joan Ebert, without whom this book might not have happened, for her dedication and persistence in managing the manuscripts in the face of great prevarication. We are enormously indebted to the team of authors who took time out from their investigations to consider their work in a broader context and share it with us all.

DAVID LANE  
*A\*Star, Singapore*

ARNIE LEVINE  
*Institute for Advanced Study, Princeton*

# Index

## A

- ABP (amyloid  $\beta$ -peptide), 330  
ACC (adrenocortical carcinoma), 141, 142  
Acetylation, 255–257  
Actinomycin D, 307, 310  
Acute ischemia, 324–325  
Acute myeloid leukemia (AML), 46  
Adenovirus gene therapy, 294–295  
Adrenocortical carcinoma (ACC), 141, 142  
ADULT syndrome, 58  
Advexin, 293, 294  
AEC (Hay-Wells syndrome), 58, 216  
Aflatoxin B1, 145–146  
African Americans, 214  
Africans, 2–4  
Aging and longevity  
    conclusions and future studies, 232–233  
    life-span reduction in p53 null mice, 222  
    p53's role in humans, 325–327  
    regulation in mice, 229–232  
AKT. *See* IGF-1/AKT/mTOR pathways  
Akt kinase, 112–114  
Alzheimer's disease, 330  
Amino-terminal transactivation domain (TAD), 26–28,  
    49, 50–51, 84–86  
AML (acute myeloid leukemia), 46  
Amphioxus, 8  
AMPK (AMP-activated protein kinase), 200–201, 203  
Amyloid  $\beta$ -peptide (ABP), 330  
Ankryin repeat domain 11 (ANKD11), 116  
Ankyloblepharon, ectodermal dysplasia, and clefting  
    syndrome (AEC), 216  
Annelid worm (*Capitella*), 280  
Antirepression of p53, 176–177  
Apoptosis  
    anticancer functions of p53 and, 225–227  
    p53 as a determinant of acute radiosensitivity and,  
        320  
    p53's role in, 180–181  
    in vivo evidence for p53 role in, 257–258  
APR-246. *See* PRIMA-1<sup>MET</sup>  
ARF-Bp1, 31  
ARF gene, 11, 104, 224–225  
Arg337, 25  
Arginine, 89  
Artiodactyla, 4  
Asians, 2–4, 214  
Asp228, 32–33  
Asp352, 25  
ASPP family of proteins, 74  
Ataxia telangiectasia mutated (ATM), 101, 165,  
    223, 229  
ATM and Rad 9-related protein (ATR), 103,  
    114, 223  
Autophagy, 179–180, 201  
Autoregulation of p53  
    conclusions and future studies, 118–119  
    control of the p53/mdm2 lifeline  
        by nontranscriptional targets of p53,  
            114–115  
        by transcriptional targets of p53, 112–114  
    controls among siblings, 117–118  
    direct regulation of p53's activity, 115–117  
    loops overview, 111  
    p53/mdm2 negative-feedback loop, 111–112  
    regulation of p53 expression independent of mdm2,  
        115  
    tissues grouped according to signal response,  
        109–110
- ## B
- Balkan endemic nephropathy (BEN), 132, 134  
*Brachistoma floridae* (Florida lancelet), 281  
BRCA1, 74, 230  
Breast cancer  
    isoforms of the p53 family and, 46  
    TP53 abnormalities as biomarkers of cancer prog-  
        nosis, 147–148  
Breast Cancer Association Consortium (BCAC), 163  
BubR1, 54
- ## C
- c-Abl, 58  
*Caenorhabditis elegans* (round worms)  
    DNA binding domains and p53, 6  
    evolution of p53 and, 52  
    evolution of the functions of p53 genes and, 9  
    oligomerization domain, 25  
    p53 homologs in, 7  
    p53 superfamily in, 281–282, 285–288  
    p63/p73 homolog, 8  
    primordial functions of p53 family in, 210

## Cancer

- anticancer functions of p53 in mice
    - apoptosis, 225–227
    - attenuation of, 228–229
    - DNA damage response, 222–224
    - oncogenic stress, 224–225
    - senescence, 225–227
  - contribution of TP53 to cancers (*see* TP53 mutations in human cancers)
  - isoforms of the p53 family and, 46–47
  - metabolism and (*see* Regulation of metabolic pathways by p53)
  - mutp53 GOF (*see* Mutant p53 gain-of-function in cancer)
  - p53-based therapy (*see* p53-based cancer therapy)
  - p53/p63/p73 family pathway and, 30–33
  - p53 pathway targeting for therapies, 30–32
  - phosphorylation of serines 6 and 9 and, 86–87
  - prevention using p53, 10
  - targeting of p53 cancer mutations, 32–33
  - tetramer formation and, 25
  - therapies derived from structural information, 30
  - therapy based on p53 (*see* p53-based cancer therapy)
  - tumorigenesis role of p53 family members, 53–54
  - tumor suppression (*see* Tumor suppressive functions of p53)
- Capitella* (annelid worm), 280
- Capsaspora owczarzaki*, 282
- Carboxy-terminal regulatory domain (CTD), 28
- Cardiotoxicity, 331
- Carnavora, 4
- CARPs, 31
- Caspase-8 D302H, 162–163
- Caucasians, 2–4, 214–215
- Caveolin-1, 205
- CDK, 227
- CDKN1A, 163–164
- CEP-1, 9, 23, 25, 52, 285–288
- CHK1, 103
- Chmp4C, 205
- Choanoflagellates, 8
- Choanozoans, 280, 282
- Ciona intestinalis* (urochordate), 281
- Ciona savignyi* (urochordate), 281
- Cisplatin-induced nephrotoxicity, 331
- Clams, 8, 282–283
- Clinical outcomes from TP53 studies
  - assessment of p53 status
    - functional analysis, 145
    - gene sequencing, 144
    - immunohistochemistry, 144
    - mass spectrometry, 145
    - microarray analysis, 145
    - TP53 mutational load assay, 145
  - conclusions and future studies, 150–152

- genetic variants used as biomarkers of cancer risk and outcome, 142
- germline mutations and inherited cancer predisposition, 141–142, 143f
- microRNAs studies and, 150, 151f
- somatic mutations and, 142, 143f, 146–147
- TP53 abnormalities as biomarkers
  - of breast cancer, 147–148
  - of colorectal cancer, 147
  - of exposure to environmental carcinogens, 145–146
  - of head and neck cancers, 148
  - of hematopoietic cancers, 149
  - of lung cancer, 148–149
  - of lymphoid cancers, 149
  - of ovarian cancer, 149
  - of prostate cancer, 149
  - of therapeutic response, 149–150
- cMyc, 69, 242
- Cockayne syndrome B protein (CSB), 194
- Codon72, 158–159
- Colon carcinomas, 47
- Colorectal cancer, 147
- COP1, 31, 115
- CP-31398, 301
- Crassostrea gigas* (oyster), 282–283
- CSB (Cockayne syndrome B protein), 194
- CTD (carboxy-terminal regulatory domain), 28
- Cyclin-dependent kinase cyclin A/cdk2, 114, 227
- Cyclotherapy, 310–311
- Cys220, 32–33

## D

- $\Delta$ 133p53 isoform, 42, 43, 45, 270–271
- D302H, 162–163
- Damage-regulated autophagy modulator (DRAM), 179, 203, 205
- Danio rerio*. *See* Zebrafish
- DBC1 protein, 31
- Delta9-THC, 330
- Diamond-Blackfan syndrome, 104
- Dmp53, 210
- DNA binding domains and p53, 6, 21–23, 64–66
- DNA-PK, 223
- $\Delta$ Np63 and zebrafish development, 274–275
- DRAM (damage-regulated autophagy modulator), 179, 203, 205
- DRB, 307
- Drosophila* (fruit flies)
  - DNA binding domains and p53, 6
  - evolution of p53 and, 52
  - evolution of the functions of p53 genes and, 9
  - oligomerization domain, 25
  - p53 homologs in, 7
  - p53 superfamily in, 281–282

p53 superfamily protein function in, 283–285  
p63/p73 homolog, 8  
primordial functions of p53 family in, 210

## E

Ectodermal dysplasia syndromes (ED), 58  
Ectrodactyly-ectoderma, dysplasia-clefting  
(EEC syndrome), 58, 216  
Elephant shark, 8  
Embryonal rhabdomyosarcoma (ERMS), 270  
Endosomal compartment, 204–205  
ESCRT-III, 205  
*Euprymna scolopes* (Hawaiian bobtail squid), 282–283  
EX-527, 304

## F

Fish nevi (f-nevi), 269  
Flavopiridol, 307  
Florida lancelet (*Brachistoma floridae*), 281  
4EBP1 protein, 201  
Fruit flies. *See Drosophila*

## G

Gain-of-function studies (GOF). *See* Mutant p53  
gain-of-function in cancer  
G-allele of MDM2 SNP309, 161, 214, 215–216  
Gendicine, 293, 294–295  
GI tract and p53, 323f  
Glu349, 25  
GLUT1 and GLUT4, 192  
Glutamine, 189  
Glycolysis and cancer cells, 188–189  
GOF (gain-of-function studies). *See* Mutant p53  
gain-of-function in cancer  
GSH/GSSG, 190

## H

HATs (histone acetyltransferases), 66  
Hausp (Herpes virus-associated ubiquitin-specific  
protease), 214  
Hawaiian bobtail squid (*Euprymna scolopes*), 282–283  
Hay-Wells syndrome (AEC), 58  
HCC (hepatocellular carcinomas), 145  
HD (Huntington's disease), 330  
HDACs (histone deacetylases), 302  
Head and neck cancers, 148, 294–295  
*Helobdella robusta* (leech), 280  
Hematopoietic cancers, 149  
Hepatocellular carcinomas (HCC), 145  
Herpes virus-associated ubiquitin-specific protease  
(Hausp), 214  
HIF (hypoxia inducible factor), 189, 193–194

Histone acetyltransferases (HATs), 66  
Histone deacetylases (HDACs), 302  
HUF Assay (Hupki fibroblast assay), 133–134  
Huntington's disease (HD), 330  
HupKi mouse model, 124, 133–134  
Hypoxia inducible factor (HIF), 189, 193–194

## I

IARC TP53 database, 124, 131, 147  
IGF-1/AKT/mTOR pathways  
conclusions and future studies, 205–206  
IGF-1/AKT pathway, 202  
mTOR, 11, 199–202  
p53 regulation of, 202–204  
p53 regulation of endosomal compartment,  
204–205  
IGF-BP3 protein, 203  
Inflammation and p53, 325–326  
Invertebrate p53 superfamily proteins  
in *Caenorhabditis*, 285–288  
conclusions and future studies, 288–289  
in *Drosophila*, 283–285  
function in early animals, 282  
isoforms and function in molluscs, 282–283  
phylogenetic relationship, 280–282  
Ionizing radiation, 100–103  
Ischemia, acute, 324–325  
Isoforms of the p53 family  
antibodies for, 43, 44f  
biological and molecular activities, 43, 45  
cancer and, 46–47  
conservation of dual gene structure, 40–42  
p53's function as a protein, 39–40  
of p63 and p73, 40  
regulation of expression, 45

## K

K120 acetylation, 88  
K370, 89  
KMT3C, 89

## L

L5 ribosomal protein, 114  
L11 ribosomal protein, 114  
L23 ribosomal protein, 114  
Lampreys, 8  
Lancelet, 8  
Leech (*Helobdella robusta*), 280  
Leptomycin B (LMB), 305–306  
Leu344, 24  
Leukemia inhibitory factor (LIF), 211, 215, 260  
Li-Fraumeni syndrome (LFS), 123, 126, 127f, 141–142  
Limb mammary syndrome, 58, 216

Liver toxicity, 331

LMB (Leptomycin B), 305–306

Lophotrochozoa, 280

Lung cancer, 148–149

Lymphoid cancers, 149

Lysine, 89

## M

Malignant peripheral neural sheath tumors (MPNSTs),  
268–269, 271–272

MDM2 and MDM4

activation of p53 due to cell culture stress, 104–105

amino-terminal phosphorylation and, 84–86

cancer therapies and, 30–32

conclusions and future studies, 105

control of the p53/mdm2 lifeline

by nontranscriptional targets of p53, 114–115

by transcriptional targets of p53, 112–114

G-allele SNP309, 159–162, 214, 215–216

influence on p53 cell cycle arrest, senescence, and  
apoptosis, 99–100

influence on response to ionizing radiation,  
100–103

influence on response to ultraviolet radiation,  
103–104

inhibition in response to oncogenic activation, 104

inhibition of the p53/Mdm2 interaction for cancer  
therapy, 298–300

mouse models with constitutively active p53 and,  
260–262

p53/mdm2 negative-feedback loop, 111–112

p53 pathway role in human reproduction, 214

regulation of p53, 12–14

regulation of p53 expression independent of mdm2,  
115

relationship between, 98–99

ribosomal stress and activation of p53, 104

role of, 97–98

stability of mutp53 and, 249

MDMX

cancer therapies and, 30–32

inhibitors, 300–301

MEFs (murine embryonic fibroblasts), 177, 182

Melanoma

cooperativity of p53 in BRAF mutations in zebrafish,  
269–270

isoforms of the p53 family and, 46

Metformin, 195

Methylene quinuclidinone, 302

microRNAs, 150, 151f, 272–273

miR-34a, 116–117

*mitfa*-*BRAF*<sup>V600E</sup>, 269–270

Molluscs, 280, 282–283

*Monosiga brevicollis*, 282

Mosquitos, 7

Mouse models of p53 functions

aging and longevity, 229–232

anticancer functions of p53 in mice

apoptosis, 225–227

attenuation of, 228–229

DNA damage response, 222–224

oncogenic stress, 224–225

senescence, 225–227

conclusions and future studies, 263–264

with constitutively active p53, 260–262

differentiation/development role, 259–260

disruption of the p53 pathway, 263

life-span reduction in p53 null mice, 222

mutant p53 functions, 262

p53 cell cycle arrest/senescence and tumor  
suppression, 258–259

stem cells role, 260

in vivo evidence for p53 role in apoptosis, 257–258

in vivo redundancy in upstream signals, 255–257

MPNSTs (malignant peripheral neural sheath tumors),  
268–269, 271–272

Mre1 1-Rad50-NBS1 (MRN) complex, 248

mTOR. *See* IGF-1/AKT/mTOR pathways

mtp53-codon72-Arg, 159

Murine embryonic fibroblasts (MEFs), 177, 182

Mussels, 282–283

Mutant p53 gain-of-function in cancer

animal models, 243–244

biochemical basis of

gene expression patterns effects, 245

protein-protein interactions, 248

structural subgroups of mutations, 244–245

transcriptional effects, 246–248

biological manifestations in cultured cells

antiapoptosis, 242

biological effects of mutp53, 243

cell migration and invasion, 242–243

genomic instability, 241

TGF- $\beta$  pathway, 243

conclusions and future studies, 249–250

definition of GOF, 240

history of GOF research, 240–241

stabilization of mutant p53 in cancer cells, 248–249

types of outcomes from mutations, 239–240

*Mya arenaria* (clam), 8, 282–283

*Mytilus edulis* (mussel), 282–283

*Mytilus trossulus* (mussel), 282–283

## N

NADPH, 189, 190

*Nematostella vectensis* (sea anemone), 6, 8, 9, 280,  
281–282

Neuronal development and differentiation, 56–57

NF- $\kappa$ B, 326, 330, 348, 349

Non-small cell lung carcinoma (NSCLC), 294

Nuclear export, 305–306  
Nutlins, 30, 69, 293, 300, 301, 307, 309  
Nyp-63, 6

## O

Onyx 015, 295–296  
Opisthokonts, 280  
Otototoxicity, 331  
Ovarian cancer, 149  
Oyster (*Crassostrea gigas*), 282–283

## P

p21  
activation of, 66  
cell cycle arrest and tumor suppression, 258–259  
codon31, 163–164  
MDM4 and, 98, 100  
p53 effector functions and, 177, 178, 181, 183  
p53 isoforms activities and, 40, 43, 45  
p53/mdm2 lifeline and, 112  
posttranslational modifications of p53 and, 87, 88  
senescence and, 227  
transcription initiation and, 67, 68, 70, 72, 73, 74  
p27-79C/T, 164  
p300/CBP, 26, 66–67, 84–86  
transcription modifications by, 71, 72  
P47S, 127  
p53-based cancer therapy  
activation of p53 using drug combinations, 309–310  
adenovirus-based therapy with Onyx 015, 295–296  
antisense and siRNA approaches, 296  
conclusions and future studies, 311  
current approaches, 293–294  
cyclotherapy, 310–311  
gene therapy-based approaches, 294–295  
inhibition of the p53/Mdm2 interaction, 298–300  
MdmX inhibitors, 300–301  
small molecule activation of p53  
family members in a p53 mutant or deficient  
background, 307–309  
by inhibition of nuclear export, 305–306  
by inhibition of sirtuins, 302–304  
by transcriptional inhibition and nucleolar disruption, 306–307  
via direct interaction with p53, 301–302  
small molecule approaches to, 297–298  
synthetic lethality, 298  
tumor specific vaccines use, 296–297  
p53 $\beta$  isoform, 43, 45  
p53/p63/p73 family  
cancer therapy from structural information, 30  
conclusions and future studies, 12–14, 33  
development regulation role, 11–12  
diversity signaling, 26–28  
DNA-binding domain structure, 20–21  
domain structure of the proteins, 4–5  
drug development, 346  
evolutionary history, 1–2, 9–11  
extreme carboxyl terminus behavior, 28  
functions unique to p63 and p73 (*see* p63 and p73)  
future studies  
cancer research, 350–351  
combinatorial complexity issues, 346–347  
intrinsic and extrinsic stress signals, 348–350  
model systems research's potential, 347–348  
homologs or paralogs of, 6–9  
limitations of evolutionary studies, 5–6  
pathway targeting for cancer therapy, 30–32  
regulation of metabolic pathways (*see* Regulation of metabolic pathways by p53)  
regulation of p53-mediated stress response (*see* MDM2 and MDM4)  
reproduction role (*see* Reproduction and p53)  
research history, 343–346  
SNPs in the signaling pathway (*see* Single-nucleotide polymorphisms and p53 signaling)  
structural basis of sequence-specific DNA binding, 21–23  
structural basis of tetramer formation, 23–25  
structural evolution of tetramerization, 25–26  
structure of the full-length protein, 28–30  
structure of the genes in humans, 2–4  
targeting of p53 cancer mutations, 32–33  
tumor suppressive functions (*see* Tumor suppressive functions of p53)  
p53R172R, 258, 262  
p63 and p73. *See also* p53/p63/p73 family  
conclusions and future studies, 59  
evolution of, 51–53  
functions, 50  
G4C14-to-A4T14, 164–165  
genetic abnormalities from p63 dysfunction, 58–59  
isoforms of, 40  
mutant p53 gain-of-function in cancer and, 246–248  
neuronal development and differentiation role, 56–57  
oocyte function role, 57–58  
regulation by autoregulation loops, 117–118  
skin and epithelial development role, 55, 56f  
structural features, 49–51  
tumorigenesis role, 53–54  
P72R polymorphism, 128–129, 142  
PALA, 307  
Parkinson's disease, 330  
Pathologies associated with the p53 response  
acute ischemia and, 324–325  
antitumor effects of p53, 327–328  
conclusions and future studies, 335

Pathologies associated with the p53 response

(continued)

- mechanisms underlying tissue-specific effects of p53, 322, 324
  - p53 as a determinant of acute radiosensitivity, 318–320
  - p53 as a radiosensitizer in the GI tract, 321–322, 323f
  - p53 inhibition as a therapeutic strategy, 318
  - p53's role in regulation of inflammation and aging, 325–327
  - potential applications of p53 inhibitors
    - p53 effects independent of PFT $\alpha$ , 332
    - PFT $\alpha$ , 328–329
    - PFT $\alpha$  and autophagy, 332
    - PFT $\alpha$  and neuropathology, 328–329
    - PFT $\alpha$  prevention of certain toxicities, 331
    - rescue of mice from developmentally lethal gene defects, 331–332
    - risks associated with PFT $\alpha$ , 333
  - safety issues associated with use of p53 inhibitors, 332–334
  - translation of experimental p53 suppression into clinical use, 334–335
- Pax-3 gene, 331–332
- PC4, 115–116
- Pentose phosphate pathway (PPP), 189, 190, 192
- Peptides and MDM2 inhibition, 298–300
- PFT $\alpha$ . *See* Pifithrin- $\alpha$
- PFT $\mu$ , 334
- Phikan083, 32–33, 320
- Phosphatidylinositol kinase-related family (PIKK), 200, 222–223
- Phosphorylation of p53. *See also* Posttranslational modification of p53
  - control of the p53/mdm2 lifeline and, 112–114
  - in vivo redundancy in upstream signals and, 255–257
- PI3 kinase (PI3K), 202
- Pifithrin- $\alpha$  (PFT $\alpha$ )
  - about, 328–329
  - autophagy and, 332
  - and neuropathology, 329–331
  - p53 effects independent of, 332
  - prevention of certain toxicities, 331
  - rescue of mice from developmentally lethal gene defects, 331–332
  - risks associated with, 333
- PIKK (phosphatidylinositol kinase-related family), 200, 222–223
- Pirh2, 31–32, 115
- Placozoa (*Trichoplax adherens*), 280
- PML (promyelocytic leukemia), 248
- Posttranslational modification of p53
  - acetylation's role in regulating p53 function, 87–89
  - amino-terminal phosphorylation and, 84–86

- conclusions and future studies, 90–92
  - induction and activation of p53, 83–84
  - introduction and historical perspective, 81–82
  - methyations of lysine and arginine, 89
  - phosphorylation of serines 6 and 9, 86–87
  - reversibility of, 89–90
  - sequential and interdependent character of, 82–83
- PPM1D(WIP1), 90
- PPP (pentose phosphate pathway), 189, 190, 192
- PRIMA-1<sup>MET</sup>, 30, 297–298, 301–302
- Promyelocytic leukemia (PML), 248
- Prostate cancer, 149
- PTEN, 203
- PUMA, 117, 180–181, 184
- Pyrazofurin, 307

**R**

- Radiosensitivity, 318–320
- Rapp-Hodgkin syndrome (RHS), 58, 216, 217
- RAS mutations, 270
- RCC (renal cell carcinoma), 46–47
- Reactivation of transcriptional reporter activity (RETRA), 308–309
- Reactive oxygen species (ROS), 189–190, 192–193, 201
- REDD1 and REDD2, 201
- Regulation of IGF-1/AKT/mTOR pathways. *See* IGF-1/AKT/mTOR pathways
- Regulation of metabolic pathways by p53
  - conclusions and future studies, 195
  - metabolism and cancer
    - anabolic pathways regulation, 189
    - energy production regulation, 188–189
    - ROS and cell fate, 189–190
  - role of p53
    - as an antioxidant, 192–193
    - functions of p53, 190–191
    - glycolysis regulation, 192
    - hypoxia and, 193–194
    - oxidative phosphorylation regulation, 191–192
  - tumor suppression and promotion by p53-induced pathways, 194–195
- Renal cell carcinoma (RCC), 46–47
- Renal toxicity, 331
- Reproduction and p53
  - conclusions and future studies, 217
  - fertility and, 211
  - infertility in women and, 215–216
  - p53 pathway role in humans, 213–217
  - p63, 211–213
  - p73, 213
  - primordial functions of p53 family in invertebrates, 210
  - protein domains, 210–211
- RETRA (reactivation of transcriptional reporter activity), 308–309

Rhabdomyosarcoma (RMS), 270  
RHS (Rapp-Hodgkin syndrome), 58, 216, 217  
Ribosomal stress and activation of p53, 104  
RING-finger domains of MDM2, 99  
RITA, 302  
RMS (rhabdomyosarcoma), 270  
RNA polymerase II (RNAPII), 66, 70  
ROS (reactive oxygen species), 189–190,  
192–193, 201  
Roscovitine, 307  
Round worms. *See Caenorhabditis elegans*

**S**

S46 phosphorylation, 71, 127  
S6K, 201  
S7 ribosomal protein, 114  
SAM (sterile alpha motive), 59, 210–211  
Sea anemone (*Nematostella vectensis*), 6, 8, 9, 210, 280,  
281–282  
Sea urchins, 7  
Seladin-1 (DHCR24) protein, 225  
Senescence  
  anticancer functions of p53 and, 227–228  
  mouse models of tumor suppression and, 258–259  
  p53's role in, 177–179  
Ser15, 82–83  
Ser49Cys, 165  
Serines 6 and 9, 86–87  
SHSF (split hand split foot malformation), 58, 216–217  
Single-nucleotide polymorphisms and p53 signaling  
  conclusions and future studies, 167, 168–169t  
  functional p53 pathway SNPs  
    MDM2 SNP309, 159–162  
    p53 codon72, 158–159  
  p53 pathway role in human reproduction, 213–216  
  potential functional p53 pathway SNPs  
    ATM Ser49Cys, 165  
    caspase-8 D302H, 162–163  
    p21 codon31, 163–164  
    p27-79C/T, 164  
    p73 G4C14-to-A4T14, 164–165  
  screens for identifying potential functional pathway  
    SNPs, 165–167  
siRNA approaches to cancer therapy, 296  
Sirtinol, 303–304  
Sirtuins (SIRT1), 31, 90, 116–117, 302–304  
Skin and epithelial development, 55, 56f  
Slug, 117  
SNP309, 159–162  
SNPs in the signaling pathway. *See* Single-nucleotide  
  polymorphisms and p53 signaling  
Sp1 transcription factor, 160–161  
Spinal cord death, 330–331  
*Spisula solidissima* (clam), 282–283  
Split hand split foot malformation (SHSF), 58, 216–217

Splitomycin, 304  
Sterile alpha motive (SAM), 59, 210–211  
*Strongylocentrotus purpuratus*, 280  
Super p53 mice, 231–232  
Suramin, 304  
Synapsida, 4  
Synthetic lethality, 298

**T**

TAD (transactivation domain), 26–28, 49, 50–51,  
84–86, 245–248  
TAp73, 53, 57–58, 275–276  
Tenovins, 31, 304  
3,2',3',4'-Tetrahydroxychalcone, 304  
Tetramer formation, 23–25  
TIGAR, 192  
Tobacco and G-to-T transversions, 146  
TOPORS, 31  
TP53 mutations in human cancers  
  biomarkers' use in clinics, 134–135  
  biomarkers' use in molecular  
    epidemiology, 134  
  clinical outcomes and correlates (*see* Clinical  
    outcomes from TP53 studies)  
  conclusions and future studies, 135–136  
  contribution of TP53 to cancers, 123  
  germline mutations, 126, 127f  
  mutagen-induced spectra  
    experimental systems, 133–134  
    human data, 131–133  
  polymorphisms, 127–129  
  somatic mutations, 124–126  
  structural and functional impact  
    dominant-negative and gain-of-function effects,  
      130–131  
    on protein structure, 129  
    on transcriptional activities, 129–130  
Transactivation domain (TAD), 26–28, 49, 50–51,  
84–86, 245–248  
Transcriptional regulation by p53  
  conclusions and future studies, 75  
  features commonly associated with transcriptional  
    regulators, 63–64  
  mechanics of  
    acetylation, 66  
    DNA binding, 64–66  
    p53-mediated repression, 70  
    transcription elongation, 69–70  
    transcription initiation, 66–69  
  promoter selectivity  
    binding partners, 73–75  
    modifications, 71–73  
    p53 response elements, 71  
  role as a sequence-specific DNA binding protein, 64  
*Trichoplax adherens* (placozoa), 280

TRIM24, 31

TSAP6, 204–205

TSC1-TSC2, 203

Tumor suppressive functions of p53

conclusions and future studies, 184

context dependence, 182–183

mechanisms of context

dependence, 183–184

models for p53 activation, 175–177

p53 effector functions

apoptosis, 180–181

autophagy, 179–180

cell-cycle checkpoints, 177

cellular senescence, 177–179

functions crucial to tumor suppression, 181–182

Tyr220, 32–33

## U

Ultraviolet radiation, 103–104

Urochordates, 281

## V

V217M, 127

*Vibrio fischeri*, 282–283

## W

Warburg effect, 188, 193–194, 349

## X

*Xenopus*, 6, 87, 211

## Y

Y220C, 32–33

## Z

Zebrafish

conservation of p53 structure and function in,  
267–268

cooperativity of p53 in BRAF mutations, 269–270

cooperativity of p53 in RAS mutations, 270

$\Delta 113$ p53 and, 42, 45

regulation of p53 in

$\Delta 113$ p53 regulation of p53-mediated apoptosis,  
270–271

by miRNAs, 272–273

ribosomal proteins, 271–272

ribosomal stress and activation of p53, 104

role of p53 family members in development,  
273–274

$\Delta N$ p63 and ectodermal development, 274–275

TAp73 requirement for normal embryonic  
development, 275–276

role of p53 in morpholino

toxicity, 273

tumor formation in p53 mutants, 268–269

*Zmpste24*, 230